CCDC38 Inhibitors
Chemical inhibitors of CCDC38 play a crucial role in modulating the protein's function by targeting various elements of the cytoskeletal network, which is fundamental to CCDC38's operational framework. WZ4003, a selective NUAK kinase inhibitor, disrupts cellular trafficking and structure, leading to functional inhibition of CCDC38 by altering the cellular environment it requires. Similarly, ML141, by inhibiting CDC42 GTPase, causes a disorganization of the cytoskeleton, which is essential for CCDC38's function. Blebbistatin, targeting myosin II, and Y-27632, a ROCK kinase inhibitor, both impair cytoskeletal dynamics, which in turn impacts CCDC38's functionality by disturbing the structural integrity it relies on.
Further affecting the cytoskeletal network, SMIFH2 inhibits formin-mediated actin assembly, which is necessary for CCDC38's role in maintaining cytoskeletal organization. The Arp2/3 complex, responsible for actin filament branching, is targeted by the inhibitor CK-666, leading to cytoskeletal alterations that impede CCDC38's function. BMS-5, which inhibits LIM kinase, disrupts actin filament dynamics critical for CCDC38, while LDN-193189 blocks BMP type I receptors, impacting pathways that indirectly modulate CCDC38's activity. PF-3758309's inhibition of PAK kinase alters the cytoskeletal architecture, affecting CCDC38. Additionally, STLC disrupts mitotic spindle dynamics, indirectly impacting CCDC38, which may be involved in these cellular processes. Marimastat affects CCDC38 by altering the extracellular matrix remodeling and cellular adhesion mechanisms. Lastly, GSK269962A, by inhibiting Rho-kinase, affects the cellular infrastructure and thus impacts the functions associated with CCDC38. Each chemical, through its specific target within the cytoskeletal network, contributes to the functional inhibition of CCDC38.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective NUAK kinase inhibitor. Given that NUAK kinases can regulate cellular trafficking and structure, inhibition of NUAK by WZ4003 could disrupt these processes, leading to functional inhibition of CCDC38, which is known to be involved in the maintenance of cytoskeletal organization. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent, selective inhibitor of CDC42 GTPase. Since CCDC38 is involved in cytoskeletal organization, inhibition of CDC42 by ML141 can lead to cytoskeletal disarray, which would functionally inhibit CCDC38 by disrupting the cellular architecture it relies on. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin is a selective inhibitor of myosin II. By inhibiting myosin II, Blebbistatin can impair cytoskeletal dynamics. This disruption can lead to functional inhibition of CCDC38, as it may rely on intact cytoskeletal structures to perform its role within the cell. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a potent inhibitor of ROCK kinases. ROCK is involved in the regulation of the actin cytoskeleton; therefore, inhibiting ROCK could compromise cytoskeletal integrity, and thus, functionally inhibit CCDC38 by perturbing the environment it operates in. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 is an inhibitor of formin-mediated actin assembly. Since CCDC38 is associated with cytoskeletal organization, inhibiting actin assembly can disrupt its function, leading to the functional inhibition of CCDC38 which depends on proper actin dynamics. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
CK-666 is an inhibitor of the Arp2/3 complex. Inhibition of the Arp2/3 complex leads to impaired actin filament branching. CCDC38, being involved in cytoskeletal organization, would be functionally inhibited due to the failure of proper actin network formation. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective inhibitor of BMP type I receptors ALK2 and ALK3, which are involved in TGF-beta signaling pathways that influence cytoskeletal dynamics. Inhibition of these receptors can disrupt cellular processes vital for CCDC38's functional role. | ||||||
PF-3758309 | 898044-15-0 | sc-478493 | 10 mg | $260.00 | ||
PF-3758309 is a potent inhibitor of PAK, a kinase that regulates cytoskeletal remodeling. Inhibiting PAK activity can lead to a functional inhibition of CCDC38 by altering the cytoskeletal architecture it requires to function properly. | ||||||
S-Trityl-L-cysteine | 2799-07-7 | sc-202799 sc-202799A | 1 g 5 g | $32.00 $66.00 | 6 | |
STLC is an inhibitor of the Eg5 kinesin motor protein, disrupting mitotic spindle formation. By disrupting spindle dynamics, STLC can indirectly inhibit the function of CCDC38 that may be involved in spindle-related processes. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase inhibitor. By inhibiting extracellular matrix remodeling, Marimastat could affect the cellular adhesion and signaling mechanisms, indirectly leading to functional inhibition of CCDC38 involved in these processes. | ||||||